Medications
Is tirzepatide a GLP-1? Yes, and something more
July 23, 2026 · 2 min read
The short answer
Yes, tirzepatide (Mounjaro, Zepbound) is a GLP-1 receptor agonist, so it belongs to the broad GLP-1 family. But it is more than that: it also activates the GIP receptor, making it a dual GIP and GLP-1 receptor agonist, sometimes called a 'twincretin'.
That dual action distinguishes it from GLP-1-only drugs like semaglutide (Ozempic, Wegovy) and liraglutide, and is part of why tirzepatide generally produced greater average weight loss in trials. Both types share a similar core mechanism and side-effect profile.
Is tirzepatide a GLP-1?
Yes. Tirzepatide (the drug in Mounjaro and Zepbound) is a GLP-1 receptor agonist, so it is correct to call it part of the GLP-1 family and it is often grouped with drugs like Ozempic and Wegovy. But there is an important extra detail that makes it a bit different from the others: tirzepatide is a dual agonist. It activates two incretin receptors, not one.
The GIP part: what makes it a "twincretin"
Incretins are gut hormones that help control blood sugar and appetite. The two main ones are GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Older drugs in this space, including semaglutide and liraglutide, act only on the GLP-1 receptor. Tirzepatide acts on both the GLP-1 receptor and the GIP receptor, which is why it is sometimes called a "twincretin" or a dual GIP/GLP-1 receptor agonist. So it is a GLP-1 drug and more.
Why the difference matters
Adding GIP activity appears to enhance the effects on appetite and metabolism. In trials, tirzepatide generally produced greater average weight loss than the GLP-1-only semaglutide, and a head-to-head diabetes trial favored tirzepatide on both weight and blood-sugar control. That dual mechanism is a large part of why. It does not, however, change the fundamentals much: the core way it curbs appetite and slows the stomach is similar, and so is the side-effect profile (the same gut effects and class cautions). Our semaglutide vs tirzepatide post and Wegovy vs Mounjaro post compare them directly.
The naming, cleared up
A few related points people often ask: Mounjaro and Zepbound are both tirzepatide (Mounjaro for diabetes, Zepbound for weight management), so both are dual GIP/GLP-1 agonists. Tirzepatide is also a peptide, which our is tirzepatide a peptide post covers, and it is not the same molecule as semaglutide. So the short answer to "is tirzepatide a GLP-1" is yes, with the useful footnote that it is a dual-acting one. This article is general information, not medical advice.
Questions people ask
Is tirzepatide a GLP-1 drug?
Yes. Tirzepatide (Mounjaro, Zepbound) is a GLP-1 receptor agonist, so it belongs to the GLP-1 family. But it is also a GIP receptor agonist, making it a dual-acting 'twincretin', which sets it apart from GLP-1-only drugs like semaglutide.
What is the difference between tirzepatide and a regular GLP-1?
Regular GLP-1 drugs like semaglutide and liraglutide act only on the GLP-1 receptor. Tirzepatide acts on both the GLP-1 and GIP receptors. That dual action appears to enhance appetite and metabolic effects and is part of why it generally produced greater weight loss in trials.
Is Mounjaro or Zepbound a GLP-1?
Both are tirzepatide, which is a GLP-1 receptor agonist, so yes, they are GLP-1 drugs, and specifically dual GIP/GLP-1 agonists. Mounjaro is approved for type 2 diabetes and Zepbound for weight management, but the molecule and its mechanism are the same.
Is tirzepatide the same as semaglutide?
No. Both are in the GLP-1 family, but they are different molecules. Semaglutide (Ozempic, Wegovy) acts only on the GLP-1 receptor, while tirzepatide also acts on the GIP receptor. Their side-effect profiles are similar, but tirzepatide generally produced more weight loss.
References
- 1.Reviews of dual GIP and GLP-1 receptor agonist pharmacology. Find on PubMed ↗
- 2.Mounjaro and Zepbound (tirzepatide) prescribing information: dosing, adverse reactions, and warnings. View label on DailyMed ↗
- 3.Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. SURPASS-2. NEJM 2021. Find on PubMed ↗
This article is general education, not medical advice. DoseLog is a tracking and reflection tool. Decisions about your medication, dose, and symptoms belong with a licensed clinician.
Keep reading